20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
SpyGlass Pharma, Inc. (SGP) operates in the BIOTECHNOLOGY industry and is headquartered in Irvine, United States with about 76 employees. Its market capitalization is roughly $973 million. In the fiscal year ended 2025-12-31, SGP reported $0M in revenue and ($40M) in net income.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | — | — |
| Gross Margin % | — | — | — | — |
| Operating Income (EBIT) | ($62M) | ($41M) | ($27M) | ($14M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($56M) | ($40M) | ($29M) | ($13M) |
| Net Margin % | — | — | — | — |
| EBITDA | ($58M) | ($39M) | — | — |
| Earnings Per Share (EPS) | $-1.96 | $-1.25 | $-0.91 | $-0.42 |
| Shares Outstanding (M) | 33M | 32M | 32M | 32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | — | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($22M) | ($15M) | ($14M) | ($11M) | ($9M) | ($7M) | ($8M) |
| Operating Margin % | — | — | — | — | — | — | — |
| Net Income | ($20M) | ($14M) | ($13M) | ($10M) | ($9M) | ($9M) | ($8M) |
| Net Margin % | — | — | — | — | — | — | — |
| EBITDA | ($22M) | ($14M) | ($12M) | ($11M) | — | — | — |
| Earnings Per Share (EPS) | $-0.59 | $-0.69 | $-0.38 | $-0.29 | — | — | $-0.26 |
| Shares Outstanding (M) | 33M | 20M | 33M | 33M | — | — | 32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($47M) | ($33M) | ($22M) | ($12M) |
| Capital Expenditures (CapEx) | $3M | $1M | $2M | $0M |
| Free Cash Flow (FCF) | ($50M) | ($33M) | ($24M) | ($12M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($15M) | ($14M) | ($9M) | ($9M) | ($6M) | ($8M) | ($6M) |
| Capital Expenditures (CapEx) | $2M | $1M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($17M) | ($14M) | ($10M) | ($9M) | ($6M) | ($8M) | ($7M) |
| FCF Margin % | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets | $243M | $116M | $23M | $41M |
| Cash & Cash Equivalents | $223M | $96M | $16M | $16M |
| Total Liabilities | $11M | $215M | $84M | $74M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $232M | ($99M) | ($60M) | ($33M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SGP viewer.
About TickerBase · Data methodology & sources · Privacy · Terms